Who
Bernadette Connaughton
Director
Company insider
Files Form 4 as: Director, Halozyme Therapeutics; Director, Editas Medicine; Director, Syneos Health.
In numbers
- Trades disclosed
- 50
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $1.9M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 7 Sep 2018
- Last trade
- 10 Aug 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 11 Aug 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $167K1,626 at $102.80 | filing |
| 10 Aug 2026filed 11 Aug 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $167K1,626 at $102.80 | filing |
| 1 Jul 2026filed 2 Jul 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $76K1,000 at $76.40 | filing |
| 1 Jul 2026filed 2 Jul 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K625 at $77.21 | filing |
| 1 Jul 2026filed 2 Jul 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $76K1,000 at $76.40 | filing |
| 1 Jul 2026filed 2 Jul 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K625 at $77.21 | filing |
| 17 Jun 2026filed 22 Jun 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —51,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —51,700 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K1,625 at $66.21 | filing |
| 1 Jun 2026filed 2 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K1,625 at $66.21 | filing |
| 5 May 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,796 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,796 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K1,625 at $63.48 | filing |
| 1 May 2026filed 5 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K1,625 at $63.48 | filing |
| 5 Jan 2026filed 6 Jan 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $141K2,000 at $70.25 | filing |
| 5 Jan 2026filed 6 Jan 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $141K2,000 at $70.25 | filing |
| 1 Dec 2025filed 1 Dec 2025 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $59K829 at $71.60 | filing |
News
Allarity Therapeutics (NASDAQ:ALLR) vs. Halozyme Therapeutics (NASDAQ:HALO) Critical AnalysisHALO · themarketsdaily.com · 24 Oct 2026
0 headlines in the last 90 days name Bernadette Connaughton; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.